Additionally, treatment with the GSK-3β-specific inhibitor SB216763 also significantly represses diabetes-induced cardiac fibrosis by reducing cardiac lipid accumulation, cardiac inflammation, and nitrosation damage 113. Here, GSK3B is linked to diabetes mellitus.